Norton Healthcare physicians first in world to test cancer drug as COVID-19 treatment
A COVID-19 patient at Norton Healthcare is the first in the world to participate in a randomized Phase 2 clinical study using low-dose selinexor. This oral drug, manufactured by Karyopharm Therapeutics Inc. and marketed as XPOVIO, is currently approved at higher doses by the U.S. Food and Drug Administration (FDA) as a treatment for cancer patients with relapsed or refractory multiple myeloma. …
Research is spine group’s hallmark
It’s not unusual for the presence and expertise of Norton Leatherman Spine surgeons to be requested at medical conferences around the world. This year alone, Norton Leatherman Spine physicians served as keynote speakers at spine conferences in Denmark, Spain, Argentina and Japan, where they presented findings from recent studies. “Our team considers these opportunities an …
Norton Cancer Institute researching how to reduce infections linked to treating AML
Nohla Therapeutics initiates Phase 2 LAUNCH clinical trial to assess optimal dosage of innovative cell therapy for those with acute myeloid leukemia. A treatment made from umbilical cord blood is helping oncology and hematology specialists at Norton Cancer Institute reduce infections in patients getting high-dose chemotherapy to treat acute myeloid leukemia (AML). The intensive chemotherapy …
Research program offers clinicians opportunities
Norton Healthcare offers a wide range of research opportunities for clinicians and their practice groups, as well as clinicians partnering from other entities. More than 850 studies were active or pending through mid-December 2017. “Norton Healthcare’s research support infrastructure makes a difference in both physician recruitment and retention,” said Stephen W. Wyatt, DMD, MPH, chief …
Norton Children’s Cancer Institute launches
Norton Cancer Institute and Norton Children’s Hospital, in affiliation with the University of Louisville, have founded Norton Children’s Cancer Institute to provide improved access, new programs to treat rare tumors and benign blood disorders, and a revamped program for bone marrow transplants. Inpatients of the institute will continue to receive care at the Addison Jo …
First patient consents to lymphoma trial
Norton Cancer Institute has enlisted the first patient ever to participate in a clinical trial studying a potential new drug to treat a type of rare lymphoma. The female patient will receive a drug designed to exploit an abnormality in lymphoma cells as part of an international study. “It’s important for our patients to have …
Refractory epilepsy treatments available
Patients with refractory epilepsy face a greater risk of accidents, injuries, cognitive issues, mood disorders, social difficulties and unemployment. Norton Neuroscience Institute offers a variety of treatments that can vastly improve quality of life for these patients, including surgery, vagus nerve stimulation, dietary therapy and experimental trials. According to the Epilepsy Foundation, 3 million Americans are affected …